Predicting Nonadherence to Medications for Acute Migraine
During a migraine attack, experiencing nausea with and without vomiting is associated with nonadherence to acute migraine medication guidelines.
AAN 2019
Memantine/Cholinesterase Inhibitor Therapy Beneficial in Alzheimer Disease
Researchers sought to determine whether combining memantine with a cholinesterase inhibitor produced early and consistent improvements in cognition for patients with moderate to severe Alzheimer disease.
Metformin, Newer Oral Medications Linked to Better Cognitive Performance in T2D
Older men with type 2 diabetes who received metformin or newer hypoglycemic medication had less cognitive decline compared with those who received sulfonylureas.
Long-Term Efficacy for Parkinsonism and Safety of Zonisamide in Patients With Lewy Body Dementia Examined
Use of zonisamide showed long-term efficacy for Parkinsonism and dementia with Lewy bodies without deterioration of cognitive function.
ACE Inhibitors, ARBs May Be Effective Migraine Prophylactic Treatments
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may represent effective migraine prophylactic treatments.
Amantadine May Optimize Levodopa Regimen in Parkinson Disease Treatment
Long-term adjunctive treatment with amantadine may enable the levodopa regimen to be optimized in patients with Parkinson experiencing motor complications.
New AAN Guideline: Treating Tourette Syndrome and Other Chronic Tic Disorders
An expert subcommittee of the AAN has released an updated evidence-based clinical practice guideline on treating Tourette syndrome and other chronic tic disorders.
Rituximab-Related Serious Infections Unlikely in Multiple Sclerosis
Serious infections related to treatment with rituximab in patients with multiple sclerosis are rare and successfully resolvable.
Droxidopa Associated With Better Treatment Adherence Compared With Midodrine
Droxidopa is associated with better treatment adherence than midodrine when medication cost is noninfluential.
Decreased Response to Botulinum Toxin Type A Agents Observed Over Time
Preliminary findings showed the decrease in botulinum toxin type A therapeutic effect over time warrants further study.
